ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

FDMT vs SLDB // EV/EBITDA & P/E VALUATION

4D Molecular Therapeutics Inc. (NASDAQ) VS. Solid Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: FDMT 5 — SLDB 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (FDMT VS. SLDB) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC FDMT SLDB SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -28.30% -35.00% +6.70 FDMT /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -15.53% -22.98% +7.45 FDMT /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 5.17 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 1/9 +4.00 FDMT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 44.1 42.4 +1.79 FDMT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $706.0M $685.2M $20.9M FDMT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR FDMT REV SLDB REV FDMT GROSS % SLDB GROSS % FDMT FCF SLDB FCF
FY 2025 $85.2M $0 — — -$109.6M -$157.4M
FY 2024 $37.0K $0 — — -$138.4M -$100.7M
FY 2023 $20.7M — — — -$75.8M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
FDMT // BETA —
SLDB // BETA —